InjuryBoard Houston Archives

• Kugel Mesh Patch Recall

  Lindsay Bauer | December 22, 2006 11:10 AM | 1 Comments
  Category: Defective & Dangerous Products

  A hernia is described by doctors as a defect of gap in the abdominal muscle wall through which an intra-abdominal organ can protrude. Weakness or a small tear can cause this gap in the muscle. Ventral hernias usually occur in an area where surgery has previously been performed and are on the abdominal surface. In order to repair a ventral hernia a doctor may use the Kugel Mesh Patch,...

• Failure of Certain Composix Kugel Mesh Patches

  John Ghezzi | December 20, 2006 12:32 PM | 0 Comments
  Category: Defective & Dangerous Products

  If you had hernia repair surgery within the last 2-3 years, you may be at risk for serious physical injury and possibly death. In December 2005 and March 2006, Davol, Inc., one of the primary manufacturers of mesh prosthetics for hernia repair, recalled certain Composix Kugel Mesh Patches used during hernia repair surgery. The Composix® Kugel Mesh Patch is used to repair ventral (incisional)...

• Drug-coated Stents Receive Approval from FDA Panel

  Tiffany Farr | December 15, 2006 10:33 AM | 0 Comments
  Category: FDA & Prescription Drugs

  Despite recent findings regarding the safety of new drug-coated stents, an FDA panel has given the thumbs up for their use in the some 3 million people who currently already have them implanted. This panel concluded that while there is "unequivocal evidence" that these drug-eluting stents may cause blood clots in patients, the benefits outweigh any safety concerns. More than 60 percent of the...

• But Quinine Makes My Leg Cramps Disappear

  John Ghezzi | December 14, 2006 9:48 AM | 0 Comments
  Category: FDA & Prescription Drugs

  Many unscrupulous companies are taking advantage of our belief that herbal and natural drugs can supplement or fill in the blanks when traditional medicine and science do not have all the answers. Firms are raking in profits through the illegal marketing of dangerous drugs whose safety and effectiveness has not been approved by the FDA.This week the FDA took aggressive action against multiple...

• Proposed guidelines provide experimental drugs to critically ill

  Christen Wiese | December 11, 2006 5:53 PM | 0 Comments
  Category: Miscellaneous

  Revised federal guidelines have been proposed to the FDA regarding experimental drugs being given to the seriously ill. The revised guidelines will lay out the specifics regarding when the drugs will be given and also provide if and when the drug companies could charge for the experimental drug. Since the 1970's the FDA has made experimental drugs available to large groups of people or...

• IRC Violates OSHA Guidelines

  Lindsay Bauer | December 08, 2006 11:38 AM | 0 Comments
  Category: Miscellaneous

  International Resistive Company (IRC), a Corpus Christi, Texas facility, has been the subject of recent court action by Reich & Binstock attorney Mike Howell. The plant manufactured electronic equipment and resisters for the automotive industry. The firm is pursuing the claim on behalf of a non-smoker who died of lung cancer. The company has been the subject of repeated intensive OSHA...

• Sometimes Drug Companies Act Responsibly

  John Ghezzi | December 06, 2006 1:54 PM | 0 Comments
  Category: FDA & Prescription Drugs

  It is good to see that sometimes drug manufacturers put consumer safety ahead of corporate profits and the bottom line. On December 2, Pfizer Inc announced that it was terminating all clinical trials for torcetrapib, a highly anticipated cholesterol drug. An independent data safety monitoring board, the only entity with access to unblinded study data, recommended terminating the ILLUMINATE study...

• Federal Advisers say Celebrex for kids: OKAY.

  Allison Snoddy | December 04, 2006 5:48 PM | 0 Comments
  Category: FDA & Prescription Drugs

  On November 29, 2006 Federal advisers recommended that Pfizer Inc. can market their painkiller Celebrex to children with rheumatoid arthritis. The Food and drug Administration now is faced with making a decision of whether they will expand the approval of Celebrex.The advisers said that the benefit's outweighed the risks in a 15 to 1 vote. Celebrex is also a Cox 2 inhibitor drug along with...

• Celebrex to be Considered for Use in the Treatment of Juvenile Rheumatoid Arthritis

  Tiffany Farr | December 01, 2006 3:20 PM | 0 Comments
  Category: FDA & Prescription Drugs

  On November 29, 2006, an FDA panel voted in favor of approving the Cox-2 inhibitor, Celebrex, for the treatment of juvenile rheumatoid arthritis. Extremely debilitating, juvenile rheumatoid arthritis affects between 30,000 to 60,000 children in the United States alone. To this date, the only medications available to children for this condition were naproxen, ibuprofen, and aspirin.Celebrex, the...